Stevens-Johnson Syndrome

• 

  Subject Areas on Research

  • A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. 
  • A recent update of pharmacogenomics in drug-induced severe skin reactions. 
  • Acute and Chronic Ophthalmic Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis - A Comprehensive Review and Guide to Therapy. II. Ophthalmic Disease. 
  • Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). 
  • Biointegration of the osteo-odonto lamina in the modified osteo-odonto keratoprosthesis: engineering of tissue to restore lost vision. 
  • Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. 
  • Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. 
  • Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. 
  • Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. 
  • Cost-effectiveness of osteo-odonto keratoprosthesis in Singapore. 
  • Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. 
  • Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. 
  • Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. 
  • Genetic predisposition of life-threatening antiepileptic-induced skin reactions. 
  • Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. 
  • Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. 
  • Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. 
  • HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. 
  • HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. 
  • Hospitalization and outcomes attributed to epidermal necrolysis in the United States: predictors of mortality. 
  • Human leukocyte antigens and drug hypersensitivity. 
  • Interleukin-2-induced dermatotoxicity resembling toxic epidermal necrolysis. 
  • Medical genetics: a marker for Stevens-Johnson syndrome. 
  • Oral and maxillofacial surgeons' role in the first successful modified osteo-odonto-keratoprosthesis performed in the United States. 
  • Pharmacogenetics of toxic epidermal necrolysis. 
  • Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. Report of a patient treated with corticosteroid "pulse therapy". 
  • Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania. 
  • Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. 
  • Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. 
  • Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis--A Comprehensive Review and Guide to Therapy. I. Systemic Disease. 
  • Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. 
  • Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin. 
  • T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction. 
  • Toxic epidermal necrolysis: report of a case. 
  • Use of cyclosporine for the treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. 
  • Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage. 
  • Valdecoxib-associated acute generalized exanthematous pustulosis.